Genomic Health, Inc.: Still Waiting for Reimbursement
Genomic Health's (NASDAQ: GHDX) revenue continues to grow slowly because of a delay in Medicare reimbursement for its prostate cancer test, but the genomic test maker was still able to reduce its net loss, moving the company closer to its goal of being profitable for the entire year.
Metric
Q2 2017
Source: Fool.com


